111 related articles for article (PubMed ID: 20067943)
21. Serum concentrations of risperidone and 9-hydroxyrisperidone after administration of the long-acting injectable form of risperidone: evidence from a routine therapeutic drug monitoring service.
Castberg I; Spigset O
Ther Drug Monit; 2005 Feb; 27(1):103-6. PubMed ID: 15665755
[TBL] [Abstract][Full Text] [Related]
22. Leukopenia during therapy with risperidone long-acting injectable: two case reports.
Uzun S; Kozumplik O; Jakovljević M; Folnegović-Smalc V
J Clin Psychopharmacol; 2008 Dec; 28(6):713-4. PubMed ID: 19011449
[No Abstract] [Full Text] [Related]
23. Health resource utilization associated with switching to risperidone long-acting injection.
Young CL; Taylor DM
Acta Psychiatr Scand; 2006 Jul; 114(1):14-20. PubMed ID: 16774656
[TBL] [Abstract][Full Text] [Related]
24. Long-acting risperidone-induced periorbital edema.
Pelizza L
J Clin Psychopharmacol; 2008 Dec; 28(6):709-10. PubMed ID: 19011446
[No Abstract] [Full Text] [Related]
25. Relative bioavailability and safety of aripiprazole lauroxil, a novel once-monthly, long-acting injectable atypical antipsychotic, following deltoid and gluteal administration in adult subjects with schizophrenia.
Turncliff R; Hard M; Du Y; Risinger R; Ehrich EW
Schizophr Res; 2014 Nov; 159(2-3):404-10. PubMed ID: 25266547
[TBL] [Abstract][Full Text] [Related]
26. Valproic acid improves psychotic agitation without influencing plasma risperidone levels in schizophrenic patients.
Yoshimura R; Shinkai K; Ueda N; Nakamura J
Pharmacopsychiatry; 2007 Jan; 40(1):9-13. PubMed ID: 17327954
[TBL] [Abstract][Full Text] [Related]
27. Optimizing treatment with risperidone long-acting injections.
Ceskova E
Acta Psychiatr Scand; 2012 Dec; 126(6):479-80. PubMed ID: 23106600
[No Abstract] [Full Text] [Related]
28. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets.
Chue P; Eerdekens M; Augustyns I; Lachaux B; Molcan P; Eriksson L; Pretorius H; David AS
Eur Neuropsychopharmacol; 2005 Jan; 15(1):111-7. PubMed ID: 15572280
[TBL] [Abstract][Full Text] [Related]
29. [Pharmacoeconomic review of the use of injectable long-acting risperidone].
Bartkó G; Fehér L
Neuropsychopharmacol Hung; 2005 Dec; 7(4):199-207. PubMed ID: 16496485
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics study for hyperprolactinemia among schizophrenics switched from risperidone to risperidone long-acting injection.
Bai YM; Chen TT; Lin WK; Chang WH; Wu B; Hung CH; Chou P; Chen JY
J Clin Psychopharmacol; 2007 Jun; 27(3):306-8. PubMed ID: 17502783
[No Abstract] [Full Text] [Related]
31. Plasma concentrations of risperidone and its 9-hydroxy metabolite and their relationship to dose in schizophrenic patients: simultaneous determination by a high performance liquid chromatography with electrochemical detection.
Aravagiri M; Marder SR; Wirshing D; Wirshing WC
Pharmacopsychiatry; 1998 May; 31(3):102-9. PubMed ID: 9657237
[TBL] [Abstract][Full Text] [Related]
32. Catatonia and mild neuroleptic malignant syndrome after initiation of long-acting injectable risperidone: case report.
Mall GD; Hake L; Benjamin AB; Adityanjee A
J Clin Psychopharmacol; 2008 Oct; 28(5):572-3. PubMed ID: 18794658
[No Abstract] [Full Text] [Related]
33. Influence of age and gender on risperidone plasma concentrations.
Aichhorn W; Weiss U; Marksteiner J; Kemmler G; Walch T; Zernig G; Stelzig-Schoeler R; Stuppaeck C; Geretsegger C
J Psychopharmacol; 2005 Jul; 19(4):395-401. PubMed ID: 15982995
[TBL] [Abstract][Full Text] [Related]
34. Treating Schizophrenia With 2 Long-Acting Injectable Antipsychotic Drugs: A Case Report.
Wartelsteiner F; Hofer A
J Clin Psychopharmacol; 2015 Aug; 35(4):474-5. PubMed ID: 26075490
[No Abstract] [Full Text] [Related]
35. Plasma antipsychotic concentration and receptor occupancy, with special focus on risperidone long-acting injectable.
Medori R; Mannaert E; Gründer G
Eur Neuropsychopharmacol; 2006 May; 16(4):233-40. PubMed ID: 16326078
[TBL] [Abstract][Full Text] [Related]
36. Long-acting neuroleptics: technique for intramuscular injection.
Bélanger-Annable MC
Can Nurse; 1985 Sep; 81(8):41-3. PubMed ID: 2862986
[No Abstract] [Full Text] [Related]
37. Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: clinical studies.
Kane JM
J Clin Psychiatry; 2003; 64 Suppl 16():34-40. PubMed ID: 14680417
[TBL] [Abstract][Full Text] [Related]
38. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics.
Lindenmayer JP; Eerdekens E; Berry SA; Eerdekens M
J Clin Psychiatry; 2004 Aug; 65(8):1084-9. PubMed ID: 15323593
[TBL] [Abstract][Full Text] [Related]
39. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
40. Liquid chromatography/tandem mass spectrometry method for simultaneous determination of risperidone and its active metabolite 9-hydroxyrisperidone in human plasma.
Bhatt J; Subbaiah G; Singh S
Rapid Commun Mass Spectrom; 2006; 20(14):2109-14. PubMed ID: 16775814
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
